Back to top
more

NeuroPace (NPCE)

(Delayed Data from NSDQ)

$14.01 USD

14.01
152,876

-0.09 (-0.64%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $13.98 -0.03 (-0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Thermo Fisher Scientific (TMO) Tops Q1 Earnings and Revenue Estimates

Thermo Fisher (TMO) delivered earnings and revenue surprises of 1.62% and 1.35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates

RxSight, Inc. (RXST) delivered earnings and revenue surprises of 12.86% and 19.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Alphatec (ATEC) Reports Q3 Loss, Tops Revenue Estimates

Alphatec (ATEC) delivered earnings and revenue surprises of -9.38% and 3.18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Accuray (ARAY) Reports Q1 Loss, Misses Revenue Estimates

Accuray (ARAY) delivered earnings and revenue surprises of -500% and 8.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Lags Revenue Estimates

Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 0% and 52.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates

908 Devices Inc. (MASS) delivered earnings and revenue surprises of 0% and 2.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Abiomed (ABMD) Q1 Earnings Top Estimates

Abiomed (ABMD) delivered earnings and revenue surprises of 15.74% and 0.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates

Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 5.88% and 36.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical (SWAV) Surpasses Q1 Earnings and Revenue Estimates

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 105.26% and 5.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

LivaNova (LIVN) Lags Q1 Earnings Estimates

LivaNova (LIVN) delivered earnings and revenue surprises of -7.69% and 3.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pfizer (PFE) Q1 Earnings and Revenues Miss Estimates

Pfizer (PFE) delivered earnings and revenue surprises of -2.41% and 3.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Meridian Bioscience and NeuroPace have been highlighted as Zacks Bull and Bear of the Day

Meridian Bioscience and NeuroPace have been highlighted as Zacks Bull and Bear of the Day.

Kevin Cook headshot

Bear of the Day: NeuroPace (NPCE)

EPS estimates get slashed 50% but sales still expected to grow for this innovative epilepsy device